Higher afamin concentrations are associated with higher fatty liver indices: Population-based KORA F4/FF4 study.

IF 3.6 3区医学 Q1 MEDICINE, GENERAL & INTERNAL

European Journal of Clinical Investigation Pub Date : 2025-07-09 DOI:10.1111/eci.70095

Corinna Niersmann, Anna Zhu, Haifa Maalmi, Xinting Cai, Jana Nano, Wolfgang Rathmann, Wolfgang Koenig, Toshinari Takamura, Barbara Kollerits, Hans Dieplinger, Annette Peters, Michael Roden, Florian Kronenberg, Barbara Thorand, Christian Herder

{"title":"Higher afamin concentrations are associated with higher fatty liver indices: Population-based KORA F4/FF4 study.","authors":"Corinna Niersmann, Anna Zhu, Haifa Maalmi, Xinting Cai, Jana Nano, Wolfgang Rathmann, Wolfgang Koenig, Toshinari Takamura, Barbara Kollerits, Hans Dieplinger, Annette Peters, Michael Roden, Florian Kronenberg, Barbara Thorand, Christian Herder","doi":"10.1111/eci.70095","DOIUrl":null,"url":null,"abstract":"Background: Previous studies suggest that afamin is associated with steatotic liver diseases (SLD). However, the exact role of afamin in SLD development and fibrogenesis remains unclear. Potential modifying effects of sex and glucose tolerance status have also not been examined. Therefore, we investigated the associations of afamin with steatotic liver diseases and fibrosis defined by non-invasive tests and assessed for possible effect modifications.Methods: This study included 3080 participants from the population-based KORA F4/FF4 cohort. Cross-sectional and prospective associations (follow-up time 6.5 years) between afamin and NAFLD liver fat score (NAFLD LFS), hepatic steatosis index, fatty liver index and the fibrosis-4 index were assessed using multiple linear regression models. Models were adjusted for age, sex, body mass index, smoking status, alcohol consumption, physical activity, metabolic parameters, medication and subclinical inflammation.Results: In the cross-sectional analysis, afamin concentrations were positively associated with NAFLD LFS (β = .32; 95% CI .27-.37), hepatic steatosis index (β = .33; 95% CI .26-.39) and fatty liver index (β = 1.78; 95% CI 1.47-2.08) (all p < .001), but not with fibrosis-4 index. In the prospective analysis, higher afamin levels were associated with a higher increase only in NAFLD LFS (p < .001). Cross-sectional and prospective associations between afamin and NAFLD LFS were more pronounced in men than in women (pinteraction < .001 and .022; respectively). Cross-sectional associations between afamin and NAFLD LFS were also stronger in individuals with prediabetes or diabetes compared to those with normal glucose tolerance (pinteraction < .001).Conclusion: Higher afamin concentrations are positively associated with NAFLD LFS with potential effect modification by sex and glucose tolerance status.","PeriodicalId":12013,"journal":{"name":"European Journal of Clinical Investigation","volume":" ","pages":"e70095"},"PeriodicalIF":3.6000,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Clinical Investigation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/eci.70095","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Previous studies suggest that afamin is associated with steatotic liver diseases (SLD). However, the exact role of afamin in SLD development and fibrogenesis remains unclear. Potential modifying effects of sex and glucose tolerance status have also not been examined. Therefore, we investigated the associations of afamin with steatotic liver diseases and fibrosis defined by non-invasive tests and assessed for possible effect modifications.

Methods: This study included 3080 participants from the population-based KORA F4/FF4 cohort. Cross-sectional and prospective associations (follow-up time 6.5 years) between afamin and NAFLD liver fat score (NAFLD LFS), hepatic steatosis index, fatty liver index and the fibrosis-4 index were assessed using multiple linear regression models. Models were adjusted for age, sex, body mass index, smoking status, alcohol consumption, physical activity, metabolic parameters, medication and subclinical inflammation.

Results: In the cross-sectional analysis, afamin concentrations were positively associated with NAFLD LFS (β = .32; 95% CI .27-.37), hepatic steatosis index (β = .33; 95% CI .26-.39) and fatty liver index (β = 1.78; 95% CI 1.47-2.08) (all p < .001), but not with fibrosis-4 index. In the prospective analysis, higher afamin levels were associated with a higher increase only in NAFLD LFS (p < .001). Cross-sectional and prospective associations between afamin and NAFLD LFS were more pronounced in men than in women (p_interaction < .001 and .022; respectively). Cross-sectional associations between afamin and NAFLD LFS were also stronger in individuals with prediabetes or diabetes compared to those with normal glucose tolerance (p_interaction < .001).

Conclusion: Higher afamin concentrations are positively associated with NAFLD LFS with potential effect modification by sex and glucose tolerance status.

查看原文本刊更多论文

较高的维生素浓度与较高的脂肪肝指数相关：基于人群的KORA F4/FF4研究

背景：以往的研究表明，维生素与脂肪变性肝病（SLD）有关。然而，维生素在SLD发展和纤维形成中的确切作用尚不清楚。性别和葡萄糖耐量状态的潜在调节作用也未被研究。因此，我们通过非侵入性试验研究了维生素a与脂肪变性肝病和纤维化的关系，并评估了可能的效果改变。方法：本研究纳入了3080名来自基于人群的KORA F4/FF4队列的参与者。采用多元线性回归模型评估afamin与NAFLD肝脂肪评分（NAFLD LFS）、肝脂肪变性指数、脂肪肝指数和纤维化-4指数之间的横断面和前瞻性关联（随访时间6.5年）。根据年龄、性别、体重指数、吸烟状况、饮酒、体力活动、代谢参数、药物和亚临床炎症对模型进行了调整。结果：在横断面分析中，afamin浓度与NAFLD LFS呈正相关(β = 0.32；95% CI 0.27 - 0.37)，肝脂肪变性指数(β = 0.33；95% CI 0.26 - 0.39)和脂肪肝指数(β = 1.78；结论：较高的afamin浓度与NAFLD LFS呈正相关，并可能因性别和糖耐量状况而改变。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Journal of Clinical Investigation 医学-医学：内科

CiteScore

9.50

自引率

3.60%

发文量

192

审稿时长

1 months

期刊介绍： EJCI considers any original contribution from the most sophisticated basic molecular sciences to applied clinical and translational research and evidence-based medicine across a broad range of subspecialties. The EJCI publishes reports of high-quality research that pertain to the genetic, molecular, cellular, or physiological basis of human biology and disease, as well as research that addresses prevalence, diagnosis, course, treatment, and prevention of disease. We are primarily interested in studies directly pertinent to humans, but submission of robust in vitro and animal work is also encouraged. Interdisciplinary work and research using innovative methods and combinations of laboratory, clinical, and epidemiological methodologies and techniques is of great interest to the journal. Several categories of manuscripts (for detailed description see below) are considered: editorials, original articles (also including randomized clinical trials, systematic reviews and meta-analyses), reviews (narrative reviews), opinion articles (including debates, perspectives and commentaries); and letters to the Editor.